DAIICHI SANKYO CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4,556 JPY | -0.11% |
|
-1.89% | +17.67% |
| Apr. 10 | Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark | MT |
| Apr. 08 | AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication | MT |
Presenter SpeechSunao Manabe (Executives)Manabe speaking. Thank you very much for joining Daii...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows:
- sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis;
- other (0.2%): primarily real estate activities.
Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).
Sector
Pharmaceuticals
Calendar
2024-04-24
- Q4 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
4,561
JPY
Average target price
5,620
JPY
Spread / Average Target
+23.22%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +17.67% | 56.7B | |
| +27.81% | 676B | |
| +24.27% | 559B | |
| -7.90% | 356B | |
| +15.20% | 320B | |
| +5.45% | 286B | |
| +2.70% | 213B | |
| +0.38% | 207B | |
| -9.53% | 199B | |
| -8.15% | 142B |
- Stock Market
- Equities
- 4568 Stock
- News Daiichi Sankyo Co., Ltd.
- Transcript : Daiichi Sankyo Company, Limited, Q4 2022 Earnings Call, Apr 27, 2022
